Department of Pediatrics and Child Neurology, Oita University Faculty of Medicine, Oita, Japan.
Clin Exp Allergy. 2011 Feb;41(2):186-91. doi: 10.1111/j.1365-2222.2010.03634.x. Epub 2010 Nov 5.
Thymus-and-activation-regulated chemokine (TARC; CCL17) is related to both allergy and pregnancy, but the relationships of maternal and umbilical cord blood CCL17 to atopic dermatitis (AD) development have not yet been examined. Objective Seventy paired full-term and normal vaginal delivery newborns and their mothers were enrolled in this study.
To elucidate the pathogenesis and fetomaternal inheritance of AD in infancy, CCL17, IFN-γ-inducible protein 10 kDa (IP-10; CXCL10), soluble HLA-G (sHLA-G), IgE and eosinophil counts were examined using sera from 70 paired umbilical cord and maternal blood samples.
Serum CCL17 (r(s) =0.340, P<0.001) and sHLA-G (r(s) =0.600, P<0.001) levels showed high correlations between umbilical cord and maternal blood. Umbilical cord serum levels of CCL17 from neonates destined to develop AD in infancy were higher than in those from neonates who showed no signs of AD during infancy (median 1586.9 vs. 819.6 pg/mL, P<0.001). Serum levels of CCL17 were higher in mothers with AD than in those without AD (median 909.6 vs. 214.1 pg/mL, P<0.001). High umbilical cord serum levels of CCL17 were associated with infantile AD development even in 62 neonates born to mothers without AD (median 1514.4 vs. 740.6 pg/mL, P<0.001) and 38 neonates born to mothers with no allergies (median 1624.2 vs. 740.6 pg/mL, P<0.001). The summary estimates for umbilical cord serum CCL17 in the diagnosis of infantile AD were: sensitivity 85.7% (95% confidence interval: 72.8-98.7), specificity 73.8% (60.5-87.1), positive predictive value 68.6% (53.2-84.0) and negative predictive value 88.6% (78.0-99.1).
These findings suggest that the umbilical cord blood CCL17 may be involved in the pathogenesis of infantile AD and in fetomaternal inheritance. Serum levels of CCL17 from umbilical cord blood may be a predictive marker for AD in infancy.
胸腺激活调节趋化因子（TARC；CCL17）与过敏和妊娠有关，但尚未研究母体和脐带血 CCL17 与特应性皮炎（AD）发展之间的关系。目的：本研究纳入了 70 对足月和正常阴道分娩的新生儿及其母亲。方法：为了阐明婴儿 AD 的发病机制和胎母遗传，我们使用 70 对脐带和母亲血液样本的血清检测了 CCL17、干扰素-γ诱导蛋白 10 kDa（IP-10；CXCL10）、可溶性 HLA-G（sHLA-G）、IgE 和嗜酸性粒细胞计数。结果：脐带和母亲血液之间的血清 CCL17（r(s)=0.340，P<0.001）和 sHLA-G（r(s)=0.600，P<0.001）水平高度相关。在婴儿期发生 AD 的新生儿的脐带血清 CCL17 水平高于在婴儿期无 AD 迹象的新生儿（中位数 1586.9 与 819.6 pg/mL，P<0.001）。患有 AD 的母亲的血清 CCL17 水平高于没有 AD 的母亲（中位数 909.6 与 214.1 pg/mL，P<0.001）。即使在 62 名母亲没有 AD 出生的新生儿（中位数 1514.4 与 740.6 pg/mL，P<0.001）和 38 名母亲没有过敏史的新生儿（中位数 1624.2 与 740.6 pg/mL，P<0.001）中，高脐带血清 CCL17 水平与婴儿 AD 发展相关。婴儿 AD 诊断的脐带血清 CCL17 汇总估计值为：敏感性 85.7%（95%置信区间：72.8-98.7），特异性 73.8%（60.5-87.1），阳性预测值 68.6%（53.2-84.0）和阴性预测值 88.6%（78.0-99.1）。结论和临床相关性：这些发现表明，脐带血 CCL17 可能参与婴儿 AD 的发病机制和胎母遗传。脐带血血清 CCL17 水平可能是婴儿 AD 的预测标志物。
Zotero 插件